Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.

Trial Details

NCT ID
NCT06084299
Phase
PHASE1
Sponsor
Zhiyong Huang
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Autologous Tumor Infiltrating Lymphocytes
Locations (sample)
  • Wuhan, China|30.58333,114.26667

Key Eligibility Criteria

  • The subjects must be informed of the study before the test and voluntarily sign a written informed consent.
  • Age of the patients was between 18\~70 years
  • Eligible patients have histologically proven advanced liver cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status was 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →